Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes.

NCT ID: NCT06373653

Last Updated: 2025-02-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-11

Study Completion Date

2025-02-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase IV clinical study to demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing restful sensation to the eyes. This will be evaluated by measuring the incidence of unexpected adverse events related to the interventions, the incidence of conjunctival hyperemia and the incidence of sensation of comfort with the application, when applied by the Principal Investigator (PI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary:

-Analog visual eyestrain test score

Secondary:

* Incidence of unexpected adverse events related to the interventions
* Incidence of conjunctival hyperemia
* Incidence of sensation of ocular dryness
* Incidence of ocular irritation
* Incidence of sensation of (sleep-crust)
* Incidence of sensation of comfort with the application, when applied by the Principal Investigator (PI)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eye Strain Eye Strain of Both Eyes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Phase IV non-inferiority, open-label, controlled, comparative, multicenter, clinical study.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Open-label,

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Manzanilla Sophia®

Matricaria recutita 0.025%, Ophthalmic solution.

* Dosage: 1 drop every 4 hours (4 daily applications \[QID\]), during 7 days.
* Route of administration: Topical ophthalmic.

Group Type ACTIVE_COMPARATOR

Manzanilla Sophia®

Intervention Type DRUG

Matricaria recutita 0.025%, Ophthalmic solution.

Meticel Ofteno®

Hypromellose 0.5%. Ophthalmic solution.

* Dosage: 1 drop every 4 hours (4 daily applications \[QID\]), during 7 days
* Route of administration: Topical ophthalmic.

Group Type ACTIVE_COMPARATOR

Meticel Ofteno®

Intervention Type DRUG

Hypromellose 0.5%, Ophthalmic solution.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Manzanilla Sophia®

Matricaria recutita 0.025%, Ophthalmic solution.

Intervention Type DRUG

Meticel Ofteno®

Hypromellose 0.5%, Ophthalmic solution.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having the ability to voluntarily give their signed informed consent.
* Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.
* Age ≥18 years.
* Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO \[Tubal Ligation\]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form \[ICF\]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.
* Present on the analog visual eyestrain test score ≥ 3 on at least 4 of the included questions.

Exclusion Criteria

* History of hypersensitivity to any of the components of the drugs under investigation.
* Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.
* In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.
* Having participated in any clinical research study 30 days prior to inclusion in this study.
* Having previously participated in this same study.
* Having a single functional eye.
* Having a history of drug addiction or drug dependence current or within the last two years prior to signing the informed consent.

Elimination Criteria:

* Withdrawal of their consent to participate in the study (informed consent form).
* Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
* Non-tolerability or hypersensitivity to any of the drugs under investigation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Laboratorios Sophia S.A de C.V.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SOPHMAN-0922/IV

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety and Tolerability of PRO-185
NCT05470868 COMPLETED PHASE1
Safety and Tolerability of EO2002
NCT05587205 RECRUITING PHASE1
A Bioequivalence Study of Tobradex AF
NCT00362895 COMPLETED PHASE3